Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Hydrogenation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN116514707B reveals manganese-catalyzed asymmetric hydrogenation for high-purity pharmaceutical intermediates. Achieve cost reduction and supply chain reliability.
Patent CN116514707B reveals manganese-catalyzed asymmetric hydrogenation for high-purity pharmaceutical intermediates, offering significant supply chain and cost advantages.
Patent CN101175715B details Rh-catalyzed hydrogenation using PhanePhos for high-purity 3,3-diarylalanine intermediates, offering scalable API synthesis solutions.
Patent CN113845478B details a high-yield total synthesis of morphine derivatives. Discover supply chain security and cost reduction in pharmaceutical manufacturing with scalable routes.
Patent CN101121719A details a cost-effective route for (S)-4-ethyl-6,6-disubstituted alkoxy compounds, offering high stereoselectivity for anticancer drug manufacturing.
Patent CN109574797B reveals a green aqueous route for S-Int A. Achieve 99.9% ee and simplified purification for antifungal API manufacturing.
Patent CN103087105B details high-efficiency asymmetric hydrogenation for chiral beta-aryl amides, offering significant supply chain and cost advantages for pharmaceutical manufacturing.
Patent CN113024615A discloses efficient chiral ligands enabling cheap metal catalysis for API synthesis, offering significant cost reduction and supply chain stability.
Patent CN115991667A details a novel Pd-catalyzed method for synthesizing chiral 3-substituted indolines with high enantioselectivity, offering cost-effective solutions for API manufacturing.
Patent CN115819260B reveals a novel synthesis route for sitagliptin intermediates offering cost reduction and high purity for pharmaceutical supply chains.
Patent CN116102464B details asymmetric hydrogenation for high-purity chiral amino alcohols, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Novel ruthenium-catalyzed asymmetric hydrogenation improves yield and purity for sitagliptin intermediates ensuring cost reduction and supply chain reliability for pharmaceutical manufacturing.
Novel chiral catalytic hydrogenation route for Duvelisib reduces steps and improves safety for reliable API intermediate supply.
Patent CN117285401B details iridium-catalyzed asymmetric hydrogenation for high-purity plant growth regulators offering significant supply chain and cost advantages.
Patent CN102381990A details a cost-effective Ruthenium-catalyzed asymmetric hydrogenation route for N-benzyl phenylephrine intermediates, offering superior purity and supply chain reliability.
Novel Ru-catalyzed route for (S)-duloxetine intermediate offers high ee and yield without nitrogen protection, reducing manufacturing costs.
Novel chiral synthesis route for octahydro-2H-pyrrolo[3,4-c]pyridine derivatives offering high purity and scalable pharmaceutical intermediate production capabilities.
Patent CN110655456B details Co-catalyzed hydrogenation of E/Z mixed olefins. Offers high ee and conversion for pharmaceutical intermediates.
Patent CN104447234A details a novel synthetic route for anti-pancreatic cancer intermediates. This report analyzes cost reduction and supply chain reliability for pharmaceutical manufacturing.
High efficiency iridium catalyzed asymmetric hydrogenation process for chiral pyridine-2 6-diol intermediates ensuring supply chain stability and cost reduction.